In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2089-2093

  Geisler, Jürgen ^a   King, Nick ^b   Anker, Gun ^a   Ornati, Giorgio ^c   Di Salle, Enrico ^c   Lønning, Per Eystein ^a   Dowsett, Mitch ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; EXEMESTANE;

AROMATIZATION; ARTICLE; BREAST CANCER; CLINICAL TRIAL; ESTRADIOL BLOOD LEVEL; ESTROGEN URINE LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HORMONE SENSITIVITY; HUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANDROSTADIENES; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARBON RADIOISOTOPES; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; POSTMENOPAUSE; TRITIUM;

EID: 0031663593     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Santen, R. J., Santner, S., Davis, B., Veldhuis, J., Samojlik, E., and Ruby, E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab., 47: 1257-1265, 1978.
2. Barone, R. M., Shamonki, I. M., Siiteri, P. K., and Judd, H. L. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using Δ1-testololactone. J. Clin. Endocrinol. Metab., 49: 672-676, 1979.
3. Lønning, P. E., Dowsett, M., and Powles, T. J. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem., 35: 355-366, 1990.
4. Jones, A. L., MacNeill, F., Jacobs, S., Lønning, P. E., Dowsett, M., and Powles, T. J. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur. J. Cancer., 28A: 1712-1716, 1992.
5. Dowsett, M., Goss, P. E., Powles, T. J., Hutchinson, G., Brodie, A. M. H., Jeffcoate, S. L., and Coombes, R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res., 47: 1957-1961, 1987.
6. Dowsett, M., Cunningham, D. C., Stein, R. C., Evans, S., Dehennin, L., Hedley, A., and Coombes, R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res., 49: 1306-1312, 1989.
7. Johannessen, D. C., Engan, T., di Salle, E., Zurlo, M. G., Paolini, J., Ornati, G., Piscitelli, G., Kvinnsland, S., and Lønning, P. E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin. Cancer Res., 3: 1101-1108, 1997.
8. Jacobs, S., Lønning, P. E., Haynes, B., Griggs, L., and Dowsett, M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J. Enzyme Inhib., 4: 315-325, 1991.
9. Lønning, P. E., Jacobs, S., Jones, A., Haynes, B., Powles, T., and Dowsett, M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br. J. Cancer, 63: 789-793, 1991.
10. Dowsett, M., Jones, A., Johnston, S. R. D., Jacobs, S., Trunet, P., and Smith, I. E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res., 1: 1511-1515, 1995.
11. Evans, T. R. J., di Salle, E., Ornati, G., Lassus, M., Benedetti, M. S., Pianezzola, E., and Coombes, R. C. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res., 52: 5933-5939, 1992.
12. Bajetta, E., Zilembo, N., Noberasco, C., Martinelli, A., Mariani, L., Ferrari, L., Buzzoni, R., Greco, M., Bartoli, C., Spagnoli, I., Danesini, G. M., Artale, S., and Paolini, J. The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur. J. Cancer, 33: 587-591, 1997.
13. Lønning, P. E., Helle, S. I., Johannessen, D. C., Adlercreutz, H., Lien, E. A., Tally, M., Ekse, D., Fotsis, T., Anker, G. B., and Hall, K. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin. Endocrinol., 42: 23-30, 1995.
14. Fishman, J. Role of 2-hydroxyestrone in estrogen metabolism. J. Clin. Endocrinol. Metab., 23: 207-210, 1963.
15. Michnovicz, J. J., Adlercreutz, H., and Bradlow, H. L. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J. Natl. Cancer Inst., 89: 718-723, 1997.
16. Fotsis, T., Järvenpää, P., and Adlercreutz, H. Purification of urine for quantitation of the complete estrogen profile. J. Steroid Biochem., 12: 503-508, 1980.
17. MacNeill, F. A., Jones, A. L., Jacobs, S., Lønning, P. E., Powles, T. J., and Dowsett, M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br. J. Cancer, 66: 692-697, 1992.
18. Santen, R. J., Demers, L. M., Lynch, J., Harvey, H., Lipton, A., Mulagha, M., Hanagan, J., Garber, J. E., Henderson, I. C., Navari, R. M., and Miller, A. A. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J. Clin. Endocrinol. Metab., 73: 99-106, 1991.
19. Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Wallon, P., Kormeset, P. O., and Lønning, P. E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitior, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer, 74: 1286-1291, 1996.
20. Cocchiara, G., Allievi, C., Berardi, A., Zugnoni, P., Benedetti, M. S., and Dostert, P. Urinary metabolism of exemestane, a new aromatase inhibitor, in rat, dog, monkey and human volunteers. J. Endocrinol. Invest., 17 (Suppl. 1): 78, 1994.
21. Johnston, S. R. D., Smith, I. E., Doody, D., Jacobs, S., Robertshaw, H., and Dowsett, M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res., 54: 5875-5881, 1994.
22. Demers, L. M. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res. Treat., 30: 95-102, 1994.
23. Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomquist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., and Plourde, P. V. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III Trials. J. Clin. Oncol., 14: 2000-2011, 1996.
24. Miller, W. R. Aromatase inhibition in the treatment of advanced breast cancer. Cancer Treat. Rev., 16: 83-93, 1989.
25. Brodie, A. M. H., Garrett, W. M., Hendrickson, J. R., Tsai-Morris, C-H., Marcotte, P. A., and Robinson, C. H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids, 38: 693-702, 1981.
26. Geisler, J., Johannessen, D. C., Anker, G., and Lønning, P. E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur. J. Cancer, 32A: 789-792, 1996.
27. Murray, R., and Pitt, P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat., 35: 249-253, 1995.
28. Thürlimann, B., Paridaens, R., Serin, D., Bonneterre, J., Roché, H., Murray, R., di Salle, E., Lanzalone, S., Zurlo, M. G., and Piscitelli, G. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a Phase II multicenter multinational study. Eur. J. Cancer, 33: 1767-1773, 1997.
29. Miller, W. R. In vitro and in vivo effects of 4-hydroxyandrostenedione on steroid and tumour metabolism. In: R. C. Coombes and M. Dowsett (eds.), 4-Hydroxyandrostenedione-a new approach to hormone-dependent cancer, Vol. 180, pp. 45-49. London: Royal Society of Medicine Services Limited, 1991.